Previous studies demonstrate that STAT3 activation not merely act as a predictive biomarker for downregulated immune cells response, but also the type of immunomodulator that is strongly associated with programmed death ligand 1 (PD-L1) expression in the TME of breast cancer [15, 29, 200]. The gene discussed is STAT3; the disease is breast carcinoma.